MALVERN, Pa. & MONTRÉAL--(BUSINESS WIRE)--Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the presentation of new in-vitro data further demonstrating mechanism of action, potential targets and key pathways for the Company’s lead oncology product candidate in clinical development, obatoclax (GX15-070). This research is being presented by leading clinical oncology experts in three oral and two poster presentations at the prestigious 50th Annual Meeting of the American Society of Hematology (ASH), being held December 6-9 in San Francisco.
